ECSP12011815A - Métodos sintéticos para compuestos espiro-oxoindol - Google Patents

Métodos sintéticos para compuestos espiro-oxoindol

Info

Publication number
ECSP12011815A
ECSP12011815A ECSP12011815A ECSP12011815A EC SP12011815 A ECSP12011815 A EC SP12011815A EC SP12011815 A ECSP12011815 A EC SP12011815A EC SP12011815 A ECSP12011815 A EC SP12011815A
Authority
EC
Ecuador
Prior art keywords
espiro
oxoindol
compounds
synthetic methods
methods
Prior art date
Application number
Other languages
English (en)
Inventor
Stephan Abel
Mikhail Chafeev
Sultan Chowdhury
Jianmin Fu
Jean Jacques Cadieux
Sayed Emad El
Elke Huthmann
Thomas Isarno
Original Assignee
Xenon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Pharmaceuticals Inc filed Critical Xenon Pharmaceuticals Inc
Publication of ECSP12011815A publication Critical patent/ECSP12011815A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Esta invención se dirige a métodos para preparar ciertos derivados de espiro-oxindol, que son útiles para el tratamiento y/o prevención de enfermedades o afecciones mediadas por el canal de sodio, tal como dolor.
ECSP12011815 2009-10-14 2012-04-18 Métodos sintéticos para compuestos espiro-oxoindol ECSP12011815A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25133509P 2009-10-14 2009-10-14

Publications (1)

Publication Number Publication Date
ECSP12011815A true ECSP12011815A (es) 2012-05-30

Family

ID=43733239

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP12011815 ECSP12011815A (es) 2009-10-14 2012-04-18 Métodos sintéticos para compuestos espiro-oxoindol

Country Status (23)

Country Link
US (4) US8445696B2 (es)
EP (2) EP2488531B1 (es)
JP (3) JP5752136B2 (es)
KR (1) KR20120099429A (es)
CN (1) CN102753556B (es)
AU (2) AU2010306768B2 (es)
BR (1) BR112012008993A2 (es)
CA (1) CA2777543A1 (es)
CL (3) CL2012000953A1 (es)
CO (1) CO6531444A2 (es)
EC (1) ECSP12011815A (es)
ES (1) ES2467166T3 (es)
HK (2) HK1174908A1 (es)
HR (2) HRP20120368A2 (es)
MA (1) MA33730B1 (es)
MX (1) MX2012004373A (es)
MY (2) MY165579A (es)
NZ (3) NZ599334A (es)
PE (2) PE20121350A1 (es)
RU (2) RU2544852C2 (es)
TN (1) TN2012000171A1 (es)
WO (1) WO2011047174A1 (es)
ZA (1) ZA201202703B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY158766A (en) * 2005-04-11 2016-11-15 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
AR053710A1 (es) * 2005-04-11 2007-05-16 Xenon Pharmaceuticals Inc Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
CL2007002953A1 (es) * 2006-10-12 2008-02-01 Xenon Pharmaceuticals Inc Compuestos derivados de espiro-oxindol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del dolor, cancer, prurito, hiperplasia prostatica benigna, hipercolesterolemia.
WO2008060789A2 (en) 2006-10-12 2008-05-22 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
AU2009303468B2 (en) * 2008-10-17 2014-08-28 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
CA2741024A1 (en) 2008-10-17 2010-04-22 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
WO2011047173A2 (en) * 2009-10-14 2011-04-21 Xenon Pharmaceuticals Inc. Pharmaceutical compositions for oral administration
ES2467166T3 (es) 2009-10-14 2014-06-12 Xenon Pharmaceuticals Inc. Métodos de síntesis de compuestos de espiro-oxindol
BR112012021086A2 (pt) 2010-02-26 2016-05-17 Xenon Pharmaceuticals Inc composições farmacêuticas de composto espiro-oxindole para administração tópica e seu uso como agentes terapêuticos
GB201122113D0 (en) * 2011-12-22 2012-02-01 Convergence Pharmaceuticals Novel compounds
CA2869547A1 (en) * 2012-04-12 2013-10-17 Xenon Pharmaceuticals Inc. Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents
CN103724340A (zh) * 2012-10-15 2014-04-16 南京大学 一类具有苯并含氧杂环结构的噻唑类衍生物及其制法
CN104326922B (zh) * 2014-11-03 2016-08-17 成都百裕制药股份有限公司 替格瑞洛中间体(1r,2s)-2-(2,3-二氟苯基)环丙胺的制备方法
CN105801556A (zh) * 2014-12-31 2016-07-27 上海药谷药业有限公司 一种2,3-二氢-1,4-苯并二烷-6-羧酸化合物的制备方法
WO2016109795A1 (en) 2014-12-31 2016-07-07 Concert Pharmaceuticals, Inc. Deuterated funapide and difluorofunapide
WO2016127068A1 (en) 2015-02-05 2016-08-11 Teva Pharmaceuticals International Gmbh Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound
SG11201804936UA (en) 2015-12-18 2018-07-30 Merck Sharp & Dohme Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels
US10100060B2 (en) 2016-06-16 2018-10-16 Xenon Pharmaceuticals Inc. Asymmetric synthesis of funapide
CA3026885A1 (en) * 2016-06-16 2017-12-21 Xenon Pharmaceuticals Inc. Solid state forms of spiro-oxindole compounds
EP3592747A1 (en) 2017-03-10 2020-01-15 Council of Scientific and Industrial Research Spirooxindole compounds as gsk3 inhibitors and process for preparation thereof
CA3202764A1 (en) 2020-11-23 2022-05-27 Enanta Pharmaceuticals, Inc. Novel spiropyrrolidine derived antiviral agents
WO2022235605A1 (en) 2021-05-04 2022-11-10 Enanta Pharmaceuticals, Inc. Novel macrocyclic antiviral agents
WO2023086400A1 (en) 2021-11-12 2023-05-19 Enanta Pharmaceuticals, Inc. Novel spiropyrrolidine derived antiviral agents
US11858945B2 (en) 2021-11-12 2024-01-02 Enanta Pharmaceuticals, Inc. Alkyne-containing antiviral agents
US11912714B2 (en) 2021-11-12 2024-02-27 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
WO2023107419A1 (en) 2021-12-08 2023-06-15 Enanta Pharmaceuticals, Inc. Saturated spirocyclics as antiviral agents
US20230295175A1 (en) * 2022-03-18 2023-09-21 Enanta Pharmaceuticals, Inc. Processes for the preparation of substituted spirooxindole derivatives
CN115353499B (zh) * 2022-10-21 2023-02-28 南京远淑医药科技有限公司 一种2-卤甲基-5-三氟甲基呋喃的合成方法
US11840545B1 (en) 2023-07-14 2023-12-12 King Faisal University Spirooxindole-copper complex as novel efficient anticorrosion agent for C-steel

Family Cites Families (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3189617A (en) 1961-02-03 1965-06-15 Sterling Drug Inc 1-aryloxindoles and their preparation
DE1956237A1 (de) 1969-11-08 1971-05-13 Basf Ag Spiro-pyrrolizidon-oxindole
DE2113343A1 (de) 1971-03-19 1972-09-21 Thiemann Chem Pharm Fab Indolo[2,3-b] chinolone und Verfahren zu ihrer Herstellung
US3723459A (en) 1971-04-23 1973-03-27 Mc Neil Labor Inc 2-oxospiro (indoline -3,4{40 -thiochroman) derivatives
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
SE400966B (sv) 1975-08-13 1978-04-17 Robins Co Inc A H Forfarande for framstellning av 2-amino-3-(eller 5-)bensoyl-fenylettiksyror
US4670566A (en) 1979-07-12 1987-06-02 A. H. Robins Company, Incorporated 3-methyl-hio-4-(5-, 6-, or 7-)phenylindolindolin-2-ones
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4440785A (en) 1980-10-30 1984-04-03 A. H. Robins Company, Inc. Methods of using 2-aminobiphenylacetic acids, esters, and metal salts thereof to treat inflammation
US4438130A (en) 1981-11-12 1984-03-20 The Upjohn Company Analgesic 1-oxa-, aza- and thia-spirocyclic compounds
JPS60142984A (ja) 1983-12-28 1985-07-29 Kyorin Pharmaceut Co Ltd 新規なスピロピロリジン−２，５−ジオン誘導体およびその製造法
US4569942A (en) 1984-05-04 1986-02-11 Pfizer Inc. N,3-Disubstituted 2-oxindole-1-carboxamides as analgesic and antiinflammatory agents
JPS6130554A (ja) 1984-07-23 1986-02-12 Ono Pharmaceut Co Ltd プロスタグランジン類似化合物のある特定の立体配置を有する異性体及びそれらを有効成分として含有する治療剤
US4690943A (en) 1984-09-19 1987-09-01 Pfizer Inc. Analgesic and antiinflammatory 1,3-diacyl-2-oxindole compounds
US4721721A (en) 1984-12-18 1988-01-26 Rorer Pharmaceutical Corporation 6-(4-thiazole) compounds, cardiotonic compositions including the same, and their uses
DE3608088C2 (de) 1986-03-07 1995-11-16 Schering Ag Pharmazeutische Präparate, enthaltend Cyclodextrinclathrate von Carbacyclinderivaten
WO1993012786A1 (en) 1986-07-10 1993-07-08 Howard Harry R Jr Indolinone derivatives
HU206084B (en) 1987-07-17 1992-08-28 Schering Ag Process for producing 9-halogen-/z/-prostaglandin derivatives and pharmaceutical compositions comprising such active ingredient
US5182289A (en) 1988-06-14 1993-01-26 Schering Corporation Heterobicyclic compounds having antiinflammatory activity
WO1991001306A1 (fr) 1989-07-25 1991-02-07 Taiho Pharmaceutical Company, Limited Derive oxoindole
DE3932953A1 (de) 1989-10-03 1991-04-11 Boehringer Mannheim Gmbh Neue 2-bicyclo-benzimidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3935514A1 (de) 1989-10-25 1991-05-02 Boehringer Mannheim Gmbh Neue bicyclo-imidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5023265A (en) 1990-06-01 1991-06-11 Schering Corporation Substituted 1-H-pyrrolopyridine-3-carboxamides
US5484778C1 (en) 1990-07-17 2001-05-08 Univ Cleveland Hospitals Phthalocynine photosensitizers for photodynamic therapy and methods for their use
AU648359B2 (en) 1990-11-22 1994-04-21 Janssen Pharmaceutica N.V. Isonicotinic acid derivatives
US5116854A (en) 1991-06-28 1992-05-26 Pfizer Inc. Anti-inflammatory 1-heteroaryl-3-acyl-2-oxindoles
US5686624A (en) 1992-01-30 1997-11-11 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
FR2708605A1 (fr) 1993-07-30 1995-02-10 Sanofi Sa Dérivés du N-sulfonylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
US5663431A (en) 1992-01-30 1997-09-02 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
FR2686878B1 (fr) 1992-01-30 1995-06-30 Sanofi Elf Derives du n-sulfonyl oxo-2 indole, leur preparation, les compositions pharmaceutiques en contenant.
US5849780A (en) 1992-01-30 1998-12-15 Sanofi 1-benzenesulfonyl-1-1,3-dihydroindol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
US5314685A (en) 1992-05-11 1994-05-24 Agouron Pharmaceuticals, Inc. Anhydrous formulations for administering lipophilic agents
HUT71553A (en) 1992-08-06 1995-12-28 Warner Lambert Co 2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and which have antitumor properties
US5278162A (en) 1992-09-18 1994-01-11 The Du Pont Merck Pharmaceutical Company 3,3'-disubstituted-1,3-dihydro-2H-pyrrolo[2,3-b]heterocyclic-2-one useful in the treatment of cognitive disorders of man
US5296478A (en) 1992-10-07 1994-03-22 The Dupont Merck Pharmaceutical Co. 1-substituted oxindoles as cognition enhancers
US5776936A (en) 1992-11-13 1998-07-07 Pharmacia & Upjohn Company Marcfortine/paraherquamide derivatives useful as antiparasitic agents
DE4242451A1 (de) 1992-12-16 1994-06-23 Basf Ag Verfahren zur Herstellung von 5-Ringheterocyclen
US5298522A (en) 1993-01-22 1994-03-29 Pfizer Inc. 6-chloro-5-fluoro-3-(2-thenoyl)-2-oxindole-1-carboxamide as an analgesic and anti-inflammatory agent while maintaining a normal urine protein/creatinine ratio
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
FR2708606B1 (fr) 1993-07-30 1995-10-27 Sanofi Sa Dérivés du N-phénylalkylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
US5502072A (en) 1993-11-26 1996-03-26 Pfizer Inc. Substituted oxindoles
AT400950B (de) 1994-02-04 1996-04-25 Immodal Pharmaka Gmbh Verfahren zur technischen herstellung definierter isomerengemische aus verbindungen mit spirozyklischen - aminocarboxyl- und/oder spirozyklischen - aminocarbonyl-systemen
CN1047386C (zh) 1994-04-07 1999-12-15 西玛夫公司 新型褪黑激素拮抗物螺旋[吲哚吡咯烷丁]衍生物,其制备方法及其作为药物产品的用途
FR2722195B1 (fr) 1994-07-07 1996-08-23 Adir Nouveaux derives de 1,3-dihydro-2h-pyrrolo(2,3-b) pyridin-2-ones et oxazolo(4,5-b) pyridin-2(3h)-ones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US5618819A (en) 1994-07-07 1997-04-08 Adir Et Compagnie 1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one and oxazolo[4,5-b]pyridin-2-(3H)-one compounds
DE69520075T2 (de) 1994-12-22 2001-08-02 Smithkline Beecham Plc Tetrazyklische spiroverbindungen, verfahren zu ihrer herstellung und ihre verwendung als 5ht1d-rezeptor antagonisten
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
CA2235686C (en) 1995-10-24 2007-06-26 Sanofi Indolin-2-one derivatives, process for their production and the pharmaceutical compositions containing them
FR2740136B1 (fr) 1995-10-24 1998-01-09 Sanofi Sa Derives d'indolin-2-one, procede pour leur preparation et les compositions pharmaceutiques les contenant
HUP9600855A3 (en) 1996-04-03 1998-04-28 Egyt Gyogyszervegyeszeti Gyar Process for producing tenidap
JPH1095766A (ja) 1996-09-19 1998-04-14 Sanwa Kagaku Kenkyusho Co Ltd アセトアミド誘導体、及びその用途
FR2757157B1 (fr) 1996-12-13 1999-12-31 Sanofi Sa Derives d'indolin-2-one, procede pour leur preparation et compositions pharmaceutiques les contenant
WO1998031378A1 (de) 1997-01-20 1998-07-23 Immodal Pharmaka Gesellschaft Mbh Verfahren und stoffe zur freisetzung eines wachstumsfaktors aus endothelzellen, und nach dem verfahren freigesetzter wachstumsfaktor sowie seine verwendung
NO317155B1 (no) 1997-02-04 2004-08-30 Ono Pharmaceutical Co <omega>-cykloalkyl-prostagladin-E<N>2</N>-derivater
JP4044967B2 (ja) 1997-02-10 2008-02-06 小野薬品工業株式会社 １１，１５−ｏ−ジアルキルプロスタグランジンｅ誘導体、それらの製造方法およびそれらを有効成分として含有する薬剤
AU741482B2 (en) 1997-05-07 2001-11-29 Allergan Pharmaceuticals International Limited Intravaginal drug delivery devices for the administration of testosterone and testosterone precursors
KR20010033538A (ko) 1997-12-25 2001-04-25 오노 야꾸힝 고교 가부시키가이샤 ω-시클로알킬-프로스타글란딘 Ｅ２ 유도체
JP4087938B2 (ja) 1998-02-04 2008-05-21 高砂香料工業株式会社 ヒノキチオ−ル類の分岐サイクロデキストリン包接化合物からなる抗菌剤およびそれを含有する組成物
NZ507169A (en) 1998-04-01 2004-02-27 Cardiome Pharma Corp Aminocyclohexyl ether compounds and uses thereof
US20040038970A1 (en) 1998-06-12 2004-02-26 Societe De Conseils De Recherches Etd' Application Scientifiques, S.A.S. A Paris, France Corp. Beta-carboline compounds
US6235780B1 (en) 1998-07-21 2001-05-22 Ono Pharmaceutical Co., Ltd. ω-cycloalkyl-prostaglandin E1 derivatives
AU5227999A (en) 1998-07-27 2000-02-21 Abbott Laboratories Substituted oxazolines as antiproliferative agents
SE9900100D0 (sv) * 1999-01-15 1999-01-15 Astra Ab New compounds
US6407101B1 (en) 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6355648B1 (en) 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
BR0010482A (pt) 1999-05-21 2002-04-23 Bristol Myers Squibb Co Inibidores pirrolotriazìnicos de cinases
ES2306665T3 (es) 1999-07-21 2008-11-16 Boehringer Ingelheim Pharmaceuticals Inc. Pequeñas moleculas utiles en el tratamiento de la enfermedad inflamatoria.
PL352911A1 (en) 1999-07-21 2003-09-22 Astrazeneca Ab New compounds
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
AU1846501A (en) 1999-11-26 2001-06-04 Bionomics Limited Loci for idiopathic generalized epilepsy, mutations thereof and method using same to assess, diagnose, prognose or treat epilepsy
FR2807038B1 (fr) 2000-04-03 2002-08-16 Sanofi Synthelabo Nouveaux derives d'indolin-2-one, leur preparation et les compositions pharmaceutiques les contenant
EP1330426A4 (en) 2000-10-13 2005-09-14 Bristol Myers Squibb Co SELECTIVE MAXI-K CALIUM CHANNEL OPENING OPERATORS UNDER CONDITIONS OF HIGH INTRA-CELLULAR CALCIUM CONCENTRATIONS, METHOD AND THEIR USE
IL154928A0 (en) 2000-11-10 2003-10-31 Lilly Co Eli 3-substituted oxindole beta 3 agonists
US6670357B2 (en) 2000-11-17 2003-12-30 Bristol-Myers Squibb Company Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
US20030078278A1 (en) 2001-06-26 2003-04-24 Pfizer Inc. Spiropiperidine compounds as ligands for ORL-1 receptor
EP1444224B1 (en) 2001-08-14 2006-05-03 Eli Lilly And Company 3-substituted oxindole beta-3 agonists
CA2465207C (en) 2001-11-01 2011-01-04 Icagen, Inc. Pyrazole-amides and -sulfonamides
US7244744B2 (en) 2001-11-01 2007-07-17 Icagen, Inc. Piperidines
ATE297925T1 (de) 2001-11-20 2005-07-15 Lilly Co Eli 3-substituierte oxindol beta 3 agonisten
SE0104341D0 (sv) 2001-12-20 2001-12-20 Astrazeneca Ab New use
BR0307268A (pt) 2002-01-28 2004-12-14 Pfizer Compostos de espiropiperidina n-substituìda como ligantes para o receptor orl-1
US6995144B2 (en) 2002-03-14 2006-02-07 Eisai Co., Ltd. Nitrogen containing heterocyclic compounds and medicines containing the same
JP2006508893A (ja) 2002-03-15 2006-03-16 イーライ・リリー・アンド・カンパニー ステロイドホルモン核内レセプターモジュレーターとしてのジヒドロインドール−２−オン誘導体
US7595311B2 (en) 2002-05-24 2009-09-29 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
GB0213715D0 (en) 2002-06-14 2002-07-24 Syngenta Ltd Chemical compounds
WO2004000225A2 (en) 2002-06-25 2003-12-31 Wyeth Use of thio-oxindole derivatives in treatment of hormone-related conditions
BR0312092A (pt) 2002-06-25 2005-03-22 Wyeth Corp Uso de derivados de tio-oxindol no tratamento de distúrbios da pele
US7256218B2 (en) 2002-11-22 2007-08-14 Jacobus Pharmaceutical Company, Inc. Biguanide and dihydrotriazine derivatives
CN100558726C (zh) 2003-02-24 2009-11-11 田边三菱制药株式会社 泰妥拉唑的对映体及其在治疗中的应用
US20050038036A1 (en) 2003-05-16 2005-02-17 Pfizer Inc Treatment of bipolar disorders and associated symptoms
WO2004100954A1 (en) 2003-05-16 2004-11-25 Pfizer Products Inc. Treatment of psychotic and depressive disorders
BRPI0419067A (pt) 2003-05-16 2007-12-11 Pfizer Prod Inc método para aumento da cognição utilizando ziprasidona
EP1633361A1 (en) 2003-05-16 2006-03-15 Pfizer Products Inc. Anxiety treatments with ziprasidone
AU2004261268B2 (en) 2003-07-30 2009-03-12 Xenon Pharmaceuticals Inc. Piperazine derivatives and their use as therapeutic agents
DE10337184A1 (de) 2003-08-13 2005-03-10 Gruenenthal Gmbh Substituierte 3-Pyrrolidin-Indol-Derivate
WO2005016913A1 (en) 2003-08-19 2005-02-24 Pfizer Japan, Inc. Tetrahydroisoquinoline or isochroman compounds as orl-1 receptor ligands for the treatment of pain and cns disorders
JPWO2005035498A1 (ja) 2003-10-08 2006-12-21 住友製薬株式会社 含窒素二環性化合物の摂食調節剤としての用途
EP1557166A1 (en) 2004-01-21 2005-07-27 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders
US7507760B2 (en) 2004-01-22 2009-03-24 Neuromed Pharmaceuticals Ltd. N-type calcium channel blockers
GB0406867D0 (en) 2004-03-26 2004-04-28 F2G Ltd Antifungal agents
CN1938031A (zh) 2004-03-29 2007-03-28 默克公司 作为钠通道阻滞剂的联芳取代的吡嗪酮类
CA2561488A1 (en) 2004-03-29 2005-10-06 Pfizer Inc. Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as orl1-receptor antagonists
GT200500063A (es) 2004-04-01 2005-10-14 Metodo para tratar la esquizofrenia y/o anormalidades glucoregulatorias
US8211883B2 (en) 2004-04-01 2012-07-03 Case Western Reserve University Topical delivery of phthalocyanines
CA2562399A1 (en) 2004-04-08 2005-10-20 Topotarget A/S Diphenyl - indol-2-on compounds and their use in the treatment of cancer
AU2005237520B2 (en) 2004-04-27 2012-01-19 Wyeth Purification of progesterone receptor modulators
ZA200607620B (en) * 2004-05-05 2008-05-28 Unibioscreen Sa Naphthalimide derivatives, methods for their production and pharmaceutical composition therefrom
WO2005105753A2 (en) * 2004-05-05 2005-11-10 Unibioscreen S.A. Naphthalimide derivatives, methods for their production and pharmaceutical compositions therefrom
TWI350168B (en) 2004-05-07 2011-10-11 Incyte Corp Amido compounds and their use as pharmaceuticals
BRPI0511132A (pt) 2004-05-14 2007-11-27 Pfizer Prod Inc derivados de pirimidina e composição farmacêutica compreendendo os mesmos
WO2006012173A1 (en) 2004-06-24 2006-02-02 Incyte Corporation Amido compounds and their use as pharmaceuticals
GT200500186A (es) 2004-07-07 2006-03-02 Regimenes anticonceptivos con antagonistas del receptor de progesterona y kits
GT200500185A (es) 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
GT200500183A (es) 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
JP4677323B2 (ja) 2004-11-01 2011-04-27 キヤノン株式会社 画像処理装置及び画像処理方法
CN101103016A (zh) 2004-11-18 2008-01-09 因塞特公司 11-β羟基类固醇脱氢酶1型抑制剂及其使用方法
DE102005007694A1 (de) 2005-02-18 2006-09-21 Henkel Kgaa Mittel zum Färben von keratinhaltigen Fasern
AU2006216780B8 (en) 2005-02-22 2010-04-22 The Regents Of The University Of Michigan Small molecule inhibitors of MDM2 and uses thereof
AR053710A1 (es) 2005-04-11 2007-05-16 Xenon Pharmaceuticals Inc Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
MY158766A (en) 2005-04-11 2016-11-15 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
AR056317A1 (es) 2005-04-20 2007-10-03 Xenon Pharmaceuticals Inc Compuestos de oxindol y composicion farmaceutica
AR053713A1 (es) 2005-04-20 2007-05-16 Xenon Pharmaceuticals Inc Compuestos heterociclicos y sus usos como agentes terapeuticos
CA2603818A1 (en) 2005-04-29 2006-11-09 Wyeth Process for preparing 3,3-disubstituted oxindoles and thio-oxindoles
WO2006125048A2 (en) 2005-05-16 2006-11-23 Gilead Sciences, Inc. Hiv-integrase inhibitor compounds
SI1924264T1 (sl) 2005-09-01 2013-12-31 F. Hoffmann-La Roche Ag Diaminopirimidini kot modulatorji p2x3 in p2x2/3
JP2009543762A (ja) 2006-06-09 2009-12-10 メルク エンド カムパニー インコーポレーテッド ナトリウムチャネル遮断薬としてのベンゾアゼピノン
WO2008046082A2 (en) 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Use of heterocyclic compounds as therapeutic agents
WO2008060789A2 (en) 2006-10-12 2008-05-22 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
WO2008046087A2 (en) 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Spiro compounds and their uses as therapeutic agents
MX2009003874A (es) 2006-10-12 2009-04-22 Xenon Pharmaceuticals Inc Derivados de espiro-oxindol triciclicos y sus usos como agentes terapeuticos.
CL2007002951A1 (es) 2006-10-12 2008-02-01 Xenon Pharmaceuticals Inc Uso de compuestos derivados de espiroheterociclicos en el tratamiento de hipercolesterolemia, hiperplasia benigna de prostata, pruritis, cancer.
CL2007002953A1 (es) 2006-10-12 2008-02-01 Xenon Pharmaceuticals Inc Compuestos derivados de espiro-oxindol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del dolor, cancer, prurito, hiperplasia prostatica benigna, hipercolesterolemia.
WO2008046084A2 (en) 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Spiroheterocyclic compounds and their uses as therapeutic agents
WO2008046083A2 (en) 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Use of oxindole compounds as therapeutic agents
GB0704846D0 (en) 2007-03-13 2007-04-18 Futura Medical Dev Ltd Topical pharmaceutical formulation
WO2008117050A1 (en) 2007-03-27 2008-10-02 Astrazeneca Ab Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer
ES2672513T3 (es) 2007-05-29 2018-06-14 Intrexon Corporation Ligandos de diacilhidrazina quirales para modular la expresión genética exógena a través del complejo del receptor de ecdisona
US7982036B2 (en) * 2007-10-19 2011-07-19 Avila Therapeutics, Inc. 4,6-disubstitued pyrimidines useful as kinase inhibitors
CA2726102A1 (en) * 2008-06-11 2009-12-17 Actelion Pharmaceuticals Ltd Tetrazole compounds as orexin receptor antagonists
US20100040187A1 (en) 2008-08-12 2010-02-18 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Heat pipe nuclear fission deflagration wave reactor cooling
AU2009303468B2 (en) 2008-10-17 2014-08-28 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
CA2741024A1 (en) 2008-10-17 2010-04-22 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
WO2010053998A1 (en) 2008-11-05 2010-05-14 Xenon Pharmaceuticals, Inc. Spiro-condensed indole derivatives as sodium channel inhibitors
US20110269788A1 (en) 2008-12-29 2011-11-03 Xenon Pharmaceuticals Inc. Spiro-oxindole-derivatives as sodium channel blockers
WO2010132352A2 (en) 2009-05-11 2010-11-18 Xenon Pharmaceuticals Inc. Spiro compounds and their use as therapeutic agents
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
WO2011047173A2 (en) 2009-10-14 2011-04-21 Xenon Pharmaceuticals Inc. Pharmaceutical compositions for oral administration
ES2467166T3 (es) 2009-10-14 2014-06-12 Xenon Pharmaceuticals Inc. Métodos de síntesis de compuestos de espiro-oxindol
BR112012021086A2 (pt) 2010-02-26 2016-05-17 Xenon Pharmaceuticals Inc composições farmacêuticas de composto espiro-oxindole para administração tópica e seu uso como agentes terapêuticos
CA2869547A1 (en) 2012-04-12 2013-10-17 Xenon Pharmaceuticals Inc. Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents

Also Published As

Publication number Publication date
BR112012008993A2 (pt) 2015-09-22
JP2016130260A (ja) 2016-07-21
US20160326184A1 (en) 2016-11-10
CA2777543A1 (en) 2011-04-21
US20110087027A1 (en) 2011-04-14
EP2488531A1 (en) 2012-08-22
CL2012000953A1 (es) 2012-07-20
MX2012004373A (es) 2012-06-28
CO6531444A2 (es) 2012-09-28
PE20170202A1 (es) 2017-03-24
AU2016208347A1 (en) 2016-08-18
EP2488531B1 (en) 2014-03-26
WO2011047174A1 (en) 2011-04-21
US8742109B2 (en) 2014-06-03
CL2016001732A1 (es) 2017-01-13
PE20121350A1 (es) 2012-10-20
MA33730B1 (fr) 2012-11-01
US9695185B2 (en) 2017-07-04
CN102753556B (zh) 2015-05-13
HK1197233A1 (en) 2015-01-09
ZA201202703B (en) 2013-06-26
ES2467166T3 (es) 2014-06-12
NZ599334A (en) 2014-03-28
TN2012000171A1 (en) 2013-12-12
MY179342A (en) 2020-11-04
EP2733145A1 (en) 2014-05-21
HK1174908A1 (en) 2013-06-21
JP2015108016A (ja) 2015-06-11
CN102753556A (zh) 2012-10-24
JP5951825B2 (ja) 2016-07-13
HRP20140486T1 (hr) 2014-07-04
MY165579A (en) 2018-04-05
HRP20120368A2 (hr) 2012-06-30
CL2013003633A1 (es) 2014-05-23
NZ622072A (en) 2015-10-30
US20130072686A1 (en) 2013-03-21
RU2012119550A (ru) 2013-11-20
RU2544852C2 (ru) 2015-03-20
JP2013508290A (ja) 2013-03-07
NZ712378A (en) 2017-05-26
RU2015103694A (ru) 2015-06-27
US9260446B2 (en) 2016-02-16
US20140336390A1 (en) 2014-11-13
JP5752136B2 (ja) 2015-07-22
AU2010306768B2 (en) 2016-08-04
US8445696B2 (en) 2013-05-21
KR20120099429A (ko) 2012-09-10
AU2010306768A1 (en) 2012-05-03

Similar Documents

Publication Publication Date Title
ECSP12011815A (es) Métodos sintéticos para compuestos espiro-oxoindol
UY32730A (es) Inhibidores de cyp17
CR20140312A (es) 4-fenil-piridinas sustiuidas para el tratamiento de enfermedades relacionadas con el receptor de nk1
HN2012000798A (es) Derivados de glicosidos y usos de los mismos.
CO6571900A2 (es) Composiciones famaceúticas del compuesto espiro-oxindol para adminsitración tópica y sus usos como agentes terapeúticos
HN2009001597A (es) 4-aril-1, 4-dihidro-1,6-naftiridinamidas sustituidas y su uso
GT201300009A (es) Derivados de tetrahidro-pirido-pirimidina
CO6470866A2 (es) Enantiómeros de compuestos de espirooxindol y sus usos como agentes terapéuticos.
PA8819201A1 (es) Derivados de azetidina y ciclobutano como inhibidores de jak
HN2007015177A (es) Derivados de triazolopirazina
UY32543A (es) Análogos de isoxazol-3(2h)-ona como agentes terapéuticos
NI201200023A (es) Derivados de 5-fluoropirimidinona
CR20150067A (es) Pirazoles sustituidos como bloqueadores del canal de calcio tipo n
GT201200004A (es) Imidazoles fusionados y composiciones que los contienen para el tratamiento de enfermedades parasitarias, como por ejemplo malaria
MX2014012266A (es) Sintesis asimetricas para compuestos espiro-oxindol utiles como agentes terapeuticos.
NI201300070A (es) Ureas asimétricas y usos médicos de las mismas
MX2013002851A (es) Inhibidores de tonum pectinacetilesterasa y metodos de su uso.
CR20150070A (es) Pirrolopirazoles como bloqueadores del canal de calcio tipo n
CO6321288A2 (es) Sales de compuestos inhibidores de vih
UY31162A1 (es) Espiroindolinas como moduladores de receptores de quimioquinas
CR10998A (es) Macrolidos
BR112015003328A2 (pt) ciclopentilpirazóis como bloqueadores de canal de cálcio de tipo-n
MX2015007460A (es) Agentes para el tratamiento del dolor y usos de los mismos.
MA33932B1 (fr) Dérivés de 2-aldoximino-5-fluoropyrimidine
EA201301016A1 (ru) Применение дитиин-тетракарбоксимидов в качестве репеллентов для птиц